GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing ...

Columnist Sam Kirton thought he'd meticulously prepared for his vacation, with all his medications in store. Then an illness took him down.

Using a specialized lab technique, scientists identified early cellular changes that may help drive lung scarring in ...

Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs. Scar tissue development can interfere with the lungs’ ability to deliver oxygen to the bloodstream, as well as with ...

According to the National Institutes of Health (NIH), about 100,000 people in the U.S. have pulmonary fibrosis. Between 30,000 and 40,000 new cases are diagnosed every year. While inherited pulmonary ...

Tyvaso significantly improved a measure of lung function for IPF patients in a Phase 3 trial, which top-line data showed met ...

Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving ...

My recent pulmonary function test (PFT) results indicated a decline in all the areas it measured. That’s not unusual for me. In the spring, my PFT numbers had declined, as well, leading to a diagnosis ...